AUGX

Augmedix NasdaqCM:AUGX Stock Report

Last Price

US$1.60

Market Cap

US$59.9m

7D

6.7%

1Y

-68.9%

Updated

15 Aug, 2022

Data

Company Financials +
AUGX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AUGX Stock Overview

Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States.

Augmedix Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Augmedix
Historical stock prices
Current Share PriceUS$1.60
52 Week HighUS$6.22
52 Week LowUS$1.41
Beta0
1 Month Change-3.03%
3 Month Change-28.89%
1 Year Change-68.93%
3 Year Changen/a
5 Year Changen/a
Change since IPO-68.00%

Recent News & Updates

Aug 08

Augmedix reports Q2 results

Augmedix press release (NASDAQ:AUGX): Q2 Revenue of $7.3M misses by $0.03M. Shares +11%. GAAP Net Loss was $7.4 million compared to $4.6 million. EBITDA losses were $6.8 million compared to $3.8 million. Adjusted EBITDA losses were $5.3 million compared to $4.0 million, which excludes the Stock-based compensation expense in both periods, the Loss on extinguishment of the prior debt facility in 2022, and the negotiated reduction of previously invoiced transaction-related expenses, related to the October 2020 transactions, and lease provision write-off in 2021. Cash and restricted cash as of June 30, 2022, was $30.8 million compared to $16.7 million as of June 30, 2021.

Jan 21

Augmedix: A Splendid Long-Term Investing Opportunity

Augmedix drives its revenue growth by reducing burnout of physicians who are highly productive. The company offers physicians medical note documentation service through its Notebuilder tool. Long-term investors can accumulate the company’s shares gradually during pullbacks to maximize their gain.

Shareholder Returns

AUGXUS Healthcare ServicesUS Market
7D6.7%-1.7%3.6%
1Y-68.9%-42.8%-9.6%

Return vs Industry: AUGX underperformed the US Healthcare Services industry which returned -44.1% over the past year.

Return vs Market: AUGX underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is AUGX's price volatile compared to industry and market?
AUGX volatility
AUGX Average Weekly Movement12.1%
Healthcare Services Industry Average Movement11.7%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: AUGX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: AUGX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013706Manny Krakarishttps://www.augmedix.com

Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live and Augmedix Notes solutions that provide pre-visit documentation, such as pre-charting and digitization of previous records/patient history; during-visit documentation, including medical notes, care gap reminders, HCC reminders, and after-visit summaries; and post-visit documentation consisting of coding, orders, and referrals. The company enables clinicians to access its applications through mobile devices, such as smartphones or Google Glass.

Augmedix Fundamentals Summary

How do Augmedix's earnings and revenue compare to its market cap?
AUGX fundamental statistics
Market CapUS$59.87m
Earnings (TTM)-US$21.69m
Revenue (TTM)US$26.52m

2.3x

P/S Ratio

-2.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AUGX income statement (TTM)
RevenueUS$26.52m
Cost of RevenueUS$14.72m
Gross ProfitUS$11.80m
Other ExpensesUS$33.49m
Earnings-US$21.69m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.58
Gross Margin44.48%
Net Profit Margin-81.80%
Debt/Equity Ratio133.7%

How did AUGX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is AUGX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AUGX?

Other financial metrics that can be useful for relative valuation.

AUGX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.8x
Enterprise Value/EBITDA-2.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does AUGX's PS Ratio compare to its peers?

AUGX PS Ratio vs Peers
The above table shows the PS ratio for AUGX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average12.7x
MTBC CareCloud
0.4x7.8%US$58.7m
BTCY Biotricity
8.1x77.1%US$62.1m
MOST MobileSmith
41.3xn/aUS$62.5m
NH NantHealth
1x22.9%US$65.6m
AUGX Augmedix
2.3x28.5%US$59.9m

Price-To-Sales vs Peers: AUGX is good value based on its Price-To-Sales Ratio (2.3x) compared to the peer average (12.7x).


Price to Earnings Ratio vs Industry

How does AUGX's PE Ratio compare vs other companies in the US Healthcare Services Industry?

Price-To-Sales vs Industry: AUGX is good value based on its Price-To-Sales Ratio (2.3x) compared to the US Healthcare Services industry average (2.9x)


Price to Sales Ratio vs Fair Ratio

What is AUGX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AUGX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.3x
Fair PS Ratio3x

Price-To-Sales vs Fair Ratio: AUGX is good value based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (3x).


Share Price vs Fair Value

What is the Fair Price of AUGX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AUGX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AUGX's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Augmedix forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


2.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AUGX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AUGX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AUGX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AUGX's revenue (28.5% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: AUGX's revenue (28.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AUGX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Augmedix performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


4.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AUGX is currently unprofitable.

Growing Profit Margin: AUGX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AUGX is unprofitable, but has reduced losses over the past 5 years at a rate of 4.3% per year.

Accelerating Growth: Unable to compare AUGX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AUGX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (2.8%).


Return on Equity

High ROE: AUGX has a negative Return on Equity (-194.26%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Augmedix's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AUGX's short term assets ($36.4M) exceed its short term liabilities ($12.6M).

Long Term Liabilities: AUGX's short term assets ($36.4M) exceed its long term liabilities ($16.8M).


Debt to Equity History and Analysis

Debt Level: AUGX has more cash than its total debt.

Reducing Debt: Insufficient data to determine if AUGX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AUGX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AUGX has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 0.8% each year.


Discover healthy companies

Dividend

What is Augmedix current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AUGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AUGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AUGX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AUGX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AUGX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Manny Krakaris (63 yo)

4.33yrs

Tenure

US$1,755,675

Compensation

Mr. Emmanuel Krakaris, also known as Manny, is President, Chief Executive Officer, Secretary and Director of Augmedix, Inc. since October 2018. Mr. Krakaris served as the Chief Executive Officer and Presid...


CEO Compensation Analysis

Compensation vs Market: Manny's total compensation ($USD1.76M) is above average for companies of similar size in the US market ($USD759.98K).

Compensation vs Earnings: Manny's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AUGX's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: AUGX's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AUGX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 38%.


Top Shareholders

Company Information

Augmedix, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Augmedix, Inc.
  • Ticker: AUGX
  • Exchange: NasdaqCM
  • Founded: 2013
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Implied Market Cap: US$59.874m
  • Shares outstanding: 37.42m
  • Website: https://www.augmedix.com

Number of Employees


Location

  • Augmedix, Inc.
  • 111 Sutter Street
  • Suite 1300
  • San Francisco
  • California
  • 94104
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/15 00:00
End of Day Share Price2022/08/15 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.